Linagliptin Rowex (Linagliptin)

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which normally degrades incretin hormones such as GLP‑1 and GIP. By preserving these hormones, linagliptin increases insulin secretion and reduces glucagon release in a glucose‑dependent manner, leading to lower blood sugar.

The specific dose of Linagliptin Rowex is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and concomitant therapies. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for linagliptin in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but differs in its pharmacokinetic profile; it is primarily excreted unchanged via the bile, so dose adjustment is not required in most cases of renal impairment, unlike some alternatives that need renal dosing changes.

Store Linagliptin Rowex at ambient temperature, below 25 °C. Keep the tablets in the original blister pack, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Linagliptin Rowex is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include pancreatitis, severe allergic reactions such as anaphylaxis, bullous pemphigoid, Stevens‑Johnson syndrome, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, or signs of an allergic reaction.

Linagliptin Rowex should be avoided in individuals with a known hypersensitivity to linagliptin or any component of the formulation. It is also contraindicated in patients with a history of pancreatitis or severe hepatic disease until evaluated by a physician.